Some important considerations in the use of cyclodextrins.
Explore the source record for details and available documents.
Carbohydrate Sequence↗
Biomedical subjects
J Blanchard
Publications and source records attributed to J Blanchard.
Identification of a novel DQB1 allele DBQ1*0616.
We report here a novel DQB1 allele (DQB1*0616) identified during sequence-based HLA typing. Polymerase chain reaction with proofreading Pwo DNA polymerase and pfu DNA polymerase and subsequent sequencing yielded identical results as that with Taq DNA polymerase. Molecular cloning and sequencing confirmed that the new DQB1 allele is identical to DQB1*0602 at exon 2 except for a single nucleotide substitution (TAC-->AAC), changing codon 60 from Tyr to Asn. This is the first report of polymorphism of DQB1 alleles at codon 60.
Alleles↗
Identification of a novel HLA-DQA1 allele (DQA1*0106) by sequence-based DQA1 typing.
We report here a novel DQA1 allele (DQA1*0106) identified during sequence-based HLA-DQA1 typing. Polymerase chain reaction with proofreading pfu DNA polymerase and subsequent sequencing yielded identical results as that with Taq DNA polymerase. Molecular cloning and sequencing confirmed that the new DQA1 allele is identical to DQA1*01021/2 at exon 2 except for a single nucleotide substitution (ACT-->GCT), changing codon 44 from Thr to Ala. This is the first report of polymorphism at codon 44 of HLA-DQA1 alleles.
Alanine↗
High-resolution sequence typing of HLA-DQA1 and -DQB1 exon 2 DNA with taxonomy-based sequence analysis (TBSA) allele assignment.
High-resolution DNA sequencing of exon 2 of DQA1 and DQB1 genes that uses a taxonomy-based sequence analysis (TBSA) method to assign alleles was developed. The system uses fewer primers for polymerase chain reaction (PCR) amplification and sequencing than other methods and yields accurate DQA1 and DQB1 typing when either homozygous or heterozygous DNA samples are tested. The approach was initially corroborated by the correct typing of 10 blinded samples that had been previously typed by PCR using sequence-specific oligonucleotide probes (PCR-SSOP) or serology, and subsequently confirmed by sequencing of cloned PCR products. DNA from peripheral blood cell samples of 130 individuals enrolled in a case-control analysis of HLA determinants of abdominal aortic aneurysm were subsequently evaluated. Overall, 8 different DQA1 and 19 DQB1 alleles were identified. All 21 DQA1 heterozygous combinations and 45 of 49 DQB1 heterozygous combinations were successfully resolved with TBSA. The two pairs of heterozygous DQB1 combinations that were not unambiguously typed required sequence specific PCR amplification for correct allele identification. We conclude that the method provides precise analysis for HLA-DQ typing.
DNA↗
Comparison of the effect of medium-chain and long-chain triacylglycerols on calcium absorption in healthy subjects.
BACKGROUND: The absorption efficiency of calcium in humans is low. Some studies in infants have shown that calcium absorption can be increased by adding medium-chain triacylglycerols to the formula diet. OBJECTIVE: The effect of medium- and long-chain triacylglycerols on calcium absorption was studied in 18 healthy, young men. The results were compared with data obtained from calcium ingestion of a protein-carbohydrate formula devoid of triacylglycerols. DESIGN: Calcium absorption was measured by using a double-isotope technique and the kinetic parameters were obtained by using a deconvolution method. RESULTS: The total fractional calcium absorption measured in the presence of medium-chain triacylglycerols (0.236 +/- 0.016) or from a protein-carbohydrate formula without triacylglycerols (0.235 +/- 0.012) was not significantly different. The same result was observed with long-chain triacylglycerols (0.309 +/- 0.026) and the protein-carbohydrate formula (0.275 +/- 0.012). No kinetic parameters were significantly different regardless of the diet (protein-carbohydrate, medium-chain triacylglycerol, or long-chain triacylglycerol). This suggests that the same mechanism for calcium absorption was operative. CONCLUSIONS: Triacylglycerols had no direct effect on calcium absorption from a protein-carbohydrate formula in healthy subjects. These data do not support the use of medium-chain triacylglycerols as adjuvants to increase the absorption of calcium in healthy adults.
Adult↗
Use of the Caco-2 cell model to assess the relative lead-chelating ability of diasterioisomers of 2,3-dimercaptosuccinic acid.
The purpose of this study was to examine the mechanisms of lead (Pb) uptake by human intestinal cells and to compare the intestinal transport and relative lead-chelating ability of two diastereoisomeric forms (i.e., meso and racemic) of 2, 3-dimercaptosuccinic acid (DMSA). The model used was the human adenocarcinoma (Caco-2) cell monolayer. The Caco-2 cells were cultured in flasks for examination of cellular uptake of lead and subsequent chelation of the lead by the DMSA isomers. For assessment of the comparative intestinal transport of the diastereoisomers, the Caco-2 cells were cultured on semipermeable supports. The effects of N-ethylmaleimide and 1,25-dihydroxyvitamin D3 (vitamin D3) on the uptake of lead by the Caco-2 monolayer were examined to determine the contributions of sulfhydryl-binding and calcium-binding protein, respectively, to the lead uptake process. Analysis of lead was performed using both macro- and micro-proton-induced X-ray emission (PIXE), and DMSA was measured spectrophotometrically following derivatization with 5,5'-dithiobis-2-nitrobenzoic acid. Results from micro-PIXE imaging suggest that lead is bound on the surface of the cell, and that sulfhydryl binding may be an important step in the uptake of lead by the Caco-2 cells. Macro-PIXE results indicate that the racemic form of DMSA may be more effective in chelating lead from within the cell. Comparison of the transport of the two DMSA diastereoisomers indicates that the racemic form is transported across the Caco-2 monolayer more readily than the meso form.
Caco-2 Cells↗
Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system.
The optimal regime of antithrombotic prophylaxis for patients undergoing total knee arthroplasty (TKA) has not been established. Many surgeons employ intermittent pneumatic compression while others use low-molecular-weight heparins (LMWH) which were primarily developed for total hip arthroplasty. We compared the efficacy and safety of these two techniques in a randomised study with blinded assessment of the endpoint by phlebography. We randomised 130 patients, scheduled for elective TKA, to receive one daily subcutaneous injection of nadroparin calcium (dosage adapted to body-weight) or continuous intermittent pneumatic compression of the foot by means of the arteriovenous impulse system. A total of 108 patients (60 in the LMWH group and 48 in the mechanical prophylaxis group) had phlebography eight to 12 days after surgery. Of the 47 with deep-vein thrombosis, 16 had received LMWH (26.7%, 95% CI 16.1 to 39.7) and 31, mechanical prophylaxis (64.6%, 95% CI 49.5 to 77.8). The difference between the two groups was highly significant (p < 0.001). Only one patient in the LMWH group had severe bleeding. We conclude that one daily subcutaneous injection of calcium nadroparin in a fixed, weight-adjusted dosage scheme is superior to intermittent pneumatic compression of the foot for thromboprophylaxis after TKA. The LMWH scheme was also safe.
Adult↗
Analysis of the scientific literature on male circumcision and risk for HIV infection.
Explore the source record for details and available documents.
Circumcision, Male↗
Rejection pattern of simultaneously transplanted cardiac and skeletal muscle grafts in a rat model.
BACKGROUND: We studied the correlation of cardiac and skeletal muscle allograft rejection in a rat model to assess the feasibility of using biopsies from simultaneously transplanted skeletal muscle for surveillance of cardiac graft rejection. METHODS: Thirty Lewis rats (RT1l)) underwent simultaneous heterotopic heart and cutaneous maximus flap (HHCM) allotransplant. Seven recipient rats (control) received syngeneic HHCM grafts from Lewis donors while the remaining 23 (study group) received HHCM grafts from Brown Norway (RT1n) donors. Control rats were sacrificed after 7 days while rats in the study group were serially sacrificed at days 1-7 after transplantation. No immunosuppression was given. The tissue sections from the HHCM grafts were assessed for acute rejection based on the grading system adopted by the International Society for Heart and Lung Transplantation. RESULTS: As expected, all the control rats had no evidence of rejection. One study animal developed an infection in the skeletal muscle allograft and was excluded. Two study animals had no evidence of rejection when sacrificed 1 day after transplant. The remaining 20 rats developed acute cellular rejection in their graft(s). Upon comparison of acute cellular rejection between the heterotopic heart and the cutaneous maximus flap grafts, rejection correlated grade for grade in 75% (15 of 20 rats). All five rats that did not have identical grades of rejection had mild rejection (grades IA, IB and II). Presence or absence of rejection, therefore, correlated in 20/22 rats: 15/20 rats with cardiac rejection and 2/2 rats without cardiac rejection. CONCLUSION: Cardiac and skeletal muscle allografts have similar pattern of rejection with little grade to grade variability. The clinical implications for surveillance of cardiac rejection warrants further investigation.
Animals↗
A new rat model to study the correlation of cardiac and skeletal muscle allograft rejection.
As a first step to study the correlation of cardiac and skeletal muscle allograft rejection, we describe a new experimental rat model of simultaneous heterotopic heart and cutaneous maximus muscle flap allotransplant. Brown Norway rats were used as donors and Lewis rats as recipients. No immunosuppression was given. The grafts were revascularized with sequential end-to-side anastomosis of each vascular pedicle to the infrarenal aorta and vena cava. Syngeneic heart and cutaneous maximus muscle grafts remained functional and showed no sign of rejection at 7 days after the transplant. In contrast, both allografts developed severe rejection and functional compromise at 7 days after the transplant. Our experimental model is technically feasible and reproducible and may provide important information about the pattern of rejection of cardiac and skeletal muscle allografts.
Animals↗
Discovery and development of novel melanogenic drugs. Melanotan-I and -II.
Explore the source record for details and available documents.
Amino Acid Sequence↗
Rejection pattern of cardiac and skeletal muscle allografts: implications for surveillance of cardiac rejection.
Explore the source record for details and available documents.
Animals↗
In vitro evaluation of pluronic F127-based controlled-release ocular delivery systems for pilocarpine.
The overall objective of this study was to develop pluronic F127 (PF127)-containing formulations of pilocarpine hydrochloride (PHCL) suitable for controlled-release ocular delivery of PHCL. Various aqueous formulations were evaluated containing 1% w/v PHCL and 25% w/v PF127 alone or with one of the following additives present: poly(ethylene glycol) 4600 (PEG), poly(vinylpyrrolidone) 10,000 (PVP), poly(vinyl alcohol) 10,000 (PVA), methylcellulose 15 cP (MC), and hydroxypropyl methylcellulose 80-120 cP (HPMC). The in vitro dissolution of the PF127 formulations and the pilocarpine release profiles from them were obtained simultaneously at 34 degrees C and room temperature using a membraneless in vitro model. It was observed that the PEG- and PVP-containing PF127 formulations of PHCL dissolved the quickest and released the drug at a significantly faster rate than the control PF127 formulation, which had no additive present. The PF127 formulations of PHCL containing MC or HPMC exhibited the slowest dissolution rates and released the drug the slowest. The same rank order was observed at each temperature for the dissolution and PHCL release profiles of each formulation. On the basis of the in vitro results, the PF127 formulations of PHCL containing MC or HPMC as an additive showed potential for use as controlled-release ocular delivery systems for PHCL.
Chemistry, Pharmaceutical↗
Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model.
The overall objective of this study was to develop Pluronic F127 (PF127)-containing formulations of pilocarpine hydrochloride (PHCL) which can be used for sustained-release ocular delivery of PHCL. The PF127 formulations of PHCL containing methylcellulose (MC) or hydroxypropyl methylcellulose (HPMC) as an additive had previously exhibited the slowest dissolution rates and released the drug the slowest in vitro. This study was performed to assess the in vivo performance of these two formulations using miosis in the albino rabbit eye produced by PHCL as a measure of ocular bioavailability. The PF127MC formulation (20 microL) had a significantly greater intensity of miosis compared to the same volume of an isotonic solution of PHCL. The duration and the intensity of the miotic response increased significantly as the instilled volume of the PF127MC gel formulation increased. The miotic response, expressed as % bioactivity by assigning a value of 100% to the 20 microL PF127MC treatment, was increased as the volume instilled was reduced from 60 to 20 microL. However, no difference in bioactivity between the 60 and 100 microL volumes was observed. In addition, the 100 microL volumes of both the PF127MC and PF127HPMC gel formulations exhibited bioactivity equivalent to 20 microL of an isotonic PHCL solution. Thus, for a given instilled concentration, the larger the volume instilled the greater the amount of drug present in tear fluid and thus the higher the concentration delivered to the iris sphincter muscle and hence the greater the miotic response. However, the fraction of the dose reaching the iris sphincter muscle was greater for the smaller instilled volume. On the basis of these findings and previous in vitro results, the PF127 formulations of PHCL having MC or HPMC as an additive showed considerable potential as sustained-release ocular delivery systems for PHCL. This conclusion was based upon their ability to provide a substantial prolongation of drug action and an improvement in the ocular bioavailability of pilocarpine compared to conventional eye drops and previously utilized PF127 formulations of PHCL. It appears that ocular bioavailability can be increased more readily by altering both the rheological characteristics of the delivery system and by using a smaller dose volume.
Animals↗
A simplified and rapid high-performance liquid chromatographic assay for ketoprofen in isopropyl myristate.
A high-performance liquid chromatographic (HPLC) procedure for quantitating ketoprofen in isopropyl myristate (IPM), a compound widely used as a receptor medium in drug diffusion studies of topical aqueous-based formulations, is developed. Previously reported HPLC assays for ketoprofen in IPM have employed relatively complex and tedious methods for purifying the IPM prior to injection onto the HPLC column. The present assay method utilizes a direct injection of the IPM-based sample onto a new reversed-phase ODS column and employs ultraviolet detection at 265 nm. Propyl paraben is employed as the internal standard. The mobile phase consists of acetonitrile-methanol-water (36:54:10, v/v/v) at a flow rate of 1.2 mL/min. The calibration curves are linear (correlation coefficient r > or = 0.988) over concentration ranges of 0.625-10 micrograms/mL and 6.25-100 micrograms/mL. The within-day and between-day precision exhibit coefficients of variation of 1.3-3.3%, and the accuracy (reported as relative error of the mean) varies from -1.9% to 0.6%. The retention times for ketoprofen and propyl paraben are approximately 2.3 and 3.3 min, respectively. The total run time per sample is approximately 7 min. The minimum quantitatable concentration is approximately 0.625 microgram/mL. The assay is stability-indicating, rapid, reproducible, sensitive, and readily adaptable for assaying other non-steroidal anti-inflammatory drugs.
Anti-Inflammatory Agents, Non-Steroidal↗
Measurement of plasma D-dimer is not useful in the prediction or diagnosis of postoperative deep vein thrombosis in patients undergoing total knee arthroplasty.
Plasma D-dimer, a highly sensitive marker of venous thromboembolism, was measured using an enzyme-linked immunosorbent assay pre-operatively, on the third postoperative day, and at the time of phlebography in 118 patients undergoing elective total knee arthroplasty. Deep venous thrombosis (DVT) was detected using systematic bilateral phlebography between the eighth and 12th postoperative day in 47 (39.8%) patients. D-dimer plasma concentrations did not differ between patients who had DVT and those who had no DVT, either pre-operatively (n = 118, P = 0.63) or at the time of phlebography (n = 111, P = 0.70). On the third postoperative day, D-dimer concentration was significantly higher (P < 0.01) in the patients who had DVT (median 3270 microg/l, range 1156-9996, n = 47) than in those who did not (2287 microg/l, 685-7062, n = 64). However, receiver operating characteristics curve analysis did not provide any useful cutoff values that would allow individual diagnoses to be made. In conclusion, the results of the present study suggest that plasma measurement of D-dimer concentration is of no value for predicting, diagnosing or ruling out DVT in patients undergoing total knee arthroplasty.
Arthroplasty, Replacement, Knee↗
Liver-directed gene transfer in non-human primates.
To develop a primate model for liver-directed gene therapy, we studied several gene transfer vehicles and routes in eight rhesus monkeys (Macaca mulatta). For this purpose, we used first-generation, replication-deficient adenoviral vectors carrying the Escherichia coli lacZ gene (Ad.CMVlacZ) or a lacZ-containing plasmid (pCMV beta) with lipofectamine for transfection. The reporter gene construct was infused into either the portal vasculature, common bile duct, or saphenous vein. Adenovirus-mediated gene transfer via the portal vein resulted in expression of lacZ in over 70% of hepatocytes by days 3-7, but was accompanied by acute hepatitis. Adenovirus-mediated gene transfer via the common bile duct resulted in lacZ expression in less than 10% of hepatocytes and was accompanied by portal inflammation. The animals mounted a significant immune response, as demonstrated by adenoviral antigen-induced T-cell proliferation and production of neutralizing anti-adenovirus antibodies and antibodies to E. coli beta-galactosidase (beta-Gal). Activation of the immune response was associated with rapid decrease of the reporter gene by days 13-21. Lipofectamine-mediated gene transfer was inefficient, and no lacZ expression in the liver was detected. To limit the host immune response, 4 animals were immunosuppressed by cyclophosphamide/prednisone and then infused with the Ad.CMVlacZ via the portal vein or the saphenous vein. The monkeys showed sustained expression of lacZ for up to 35 days with no evidence of inflammation. The primates transduced via the saphenous vein showed a level of beta-Gal expression in the liver similar to that of the portal vein-infused animals. In conclusion, adenovirus-mediated gene transfer to non-human primate livers via the portal vein or saphenous vein is efficient, but it results in transient expression and is accompanied by an immune response to both vector and transgene products and acute hepatitis, whereas lipofectamine-mediated transfer is inefficient. Manipulation of the host immune response may expand potential applications of adenoviral vectors for liver-directed gene transfer.
Adenoviridae↗
Intrasplenic hepatocyte allotransplantation in dalmation dogs with and without cyclosporine immunosuppression.
Hepatocyte allotransplantation has been performed successfully in several small animal models for the amelioration of inborn metabolic errors. Before a human clinical trial of hepatocyte allotransplantation can be attempted, preliminary experience in a large animal model is needed. We transplanted isolated mongrel hepatocytes into the spleen of dalmatians in the attempt to cure their inborn error of uric acid metabolism. Of 10 dalmatian recipients, two that received 9-10 x 10(9) mongrel hepatocytes died early after surgery of acute portal hypertension and hemorrhage. The eight long-term survivors received 5-6 x 10(9) hepatocytes and were randomized either to no treatment or to oral cyclosporine (CsA). Levels of CsA were adjusted to maintain trough levels between 400 and 800 ng/ml. In the four nonimmunosuppressed dalmatians, a reproducible average reduction in urinary uric acid excretion (UUAEx) of 23.7% was achieved; values returned to baseline within 14 days. In the CsA-immunosuppressed dalmatians, the average decline in UUAEx was 30%. The partial correction of the metabolic defect persisted for an average of 25 days in three immunosuppressed dogs, whereas in one dog, the partial correction lasted for over 90 days. No change in UUAEx was observed in two dalmatians that underwent sham laparotomy and intrasplenic injection of saline solution; CsA given alone to dalmatians did not modify UUAEx. We conclude that the dalmatian dog is a valuable large animal model for studies of the role of hepatocyte transplantation in the cure of inborn hepatic metabolic errors.
Animals↗